PSA testing in asymptomatic men – a new resource for GPs
The early detection and management of prostate cancer is a complex issue. Prostate Specific Antigen (PSA) testing sometimes leads to false positives (or false negatives), overdiagnosis or overtreatment. To help GPs discuss with their patients both the potential benefits and risks of PSA testing, the National Health and Medical Research Council (NHMRC) last week released a 4-page resource titled PSA Testing for Prostate Cancer in Asymptomatic Men: Information for Health Practitioners. Developed by a multidisciplinary expert advisory group, the resource provides a summary of the evidence on the benefits and harms of PSA testing.
This information resource is also available via the AMA GP Desktop Practice Support Toolkit.